Molecule and platform
Delivery systems investigate protection, transport or release of an entity. The material of interest and its vehicle should be described separately. A result may depend on the combination rather than the peptide sequence alone.
Loading is not effective delivery
Distinguish incorporation, stability, release and arrival at the site of interest. A high loaded fraction alone does not demonstrate suitable release or the presence of intact molecules at the destination.
Comparing platforms
Compare free material, vehicle and complete formulation where the design allows. Record composition, size distribution where relevant, analytical method and medium conditions. Specify whether the readout measured the intact entity, a label or a transformation product.
Avoiding extrapolation
Do not transfer stability, bioavailability or performance between formulations without corresponding data. The review introduces specific platforms and studies; it is not a preparation or administration instruction for catalog materials.
Sources and verification scope
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines ↗
Xiao et al. · Signal Transduction and Targeted Therapy
Source details (original language)
- Scope
- Historical review reporting 28 approvals in 2014–2024 and 38 phase III candidates
- Document section
- Peptide-based drug market & clinical trial; Figure 4 and Tables 2–3
- Limitations
- Denominators differ between narrative and tables; no new percentages or current regulatory count inferred.
- Claim verification date
- 2026-09-09
Related reading
How peptides are studied: mechanisms, cells, animals and human trials
How experimental questions, models and analytical methods shape peptide research and interpretation.
Read details →Reading peptide documentation: identity, purity, content and COA
How to distinguish specifications, batch results, assay and microbiological attributes.
Read details →